Targeted Cancer Therapy

Overview

This podcast features Dr. Ben Solomon, a thoracic medical oncologist at Peter MacCallum Cancer Centre in Melbourne, Australia, discussing lung cancer trends in Australia with Dr. Jack West from City of Hope. The conversation covers Dr. Solomon's career path, the evolution of thoracic oncology, and the development of targeted therapies for ALK-positive non-small cell lung cancer (NSCLC). It highlights the importance of international collaboration in research and clinical trials, challenges in molecular testing and access to precision medicine in Australia, and the logistical difficulties faced by patients living far from metropolitan treatment centers.

Career and Focus on ALK-Positive NSCLC

Dr. Solomon shares how his interest in thoracic oncology developed during his residency and early faculty position. He recounts the serendipitous shift of a phase one trial he led from targeting MET to focusing on ALK rearrangements after a key discovery in the field. This pivot led to important international collaborations and demonstrated for the first time that targeted therapy could outperform chemotherapy for ALK-positive lung cancer patients. Dr. Solomon emphasizes the rapid progression from early trials to worldwide drug approvals and ongoing development of newer generation ALK inhibitors.

Global Collaboration in Thoracic Oncology

The discussion underscores how thoracic oncology has become increasingly global, facilitated by teleconferencing and video meetings that overcome geographic barriers. Dr. Solomon notes the value of international partnerships for advancing research and clinical trials, despite challenges such as inconvenient time zones. He stresses that global collaboration accelerates progress by leveraging expertise and patient populations worldwide.

Molecular Testing and Access Challenges in Australia

Dr. Solomon explains that molecular testing in Australia is primarily driven by drug reimbursement policies, currently covering EGFR, ALK, and ROS1 mutations due to approved targeted therapies. He acknowledges delays in drug approvals compared to the US and highlights challenges in implementing comprehensive genomic testing for rarer mutations. Geographic dispersion of the population poses additional hurdles, as many patients live far from metropolitan centers where testing and treatment are concentrated. Issues include obtaining sufficient tissue samples, timely testing, physician education, and reimbursement constraints.

Patient Access and Treatment Logistics

The podcast addresses the difficulty of delivering concurrent chemoradiation therapy to patients living outside major cities. Many patients must temporarily relocate to metropolitan areas like Melbourne or Sydney for several weeks of treatment. While regional radiotherapy centers are increasing, vast distances remain a barrier. Government programs provide some travel and accommodation support. Telehealth is emerging as a useful tool for follow-up visits, reducing travel burdens, though its use in clinical trials is still limited and under exploration.

Peter MacCallum Cancer Centre and Regional Patient Care

Dr. Solomon describes Peter MacCallum Cancer Centre as a respected institution attracting patients from across Australia and neighboring countries. However, non-Australian citizens face financial barriers due to the national healthcare system's coverage limitations. He shares an example of a patient from mainland China who chose treatment in Melbourne over Hong Kong due to language preferences, illustrating the complex factors influencing patient care decisions.

Source Information

This content is based on a 16-minute podcast episode from the International Association for the Study of Lung Cancer (IASLC) titled "Lung Cancer Trends in Australia with Dr. Ben Solomon at IASLC 2019 WCLC." The discussion is hosted by Dr. Jack West of City of Hope Comprehensive Cancer Center and features Dr. Ben Solomon from Peter MacCallum Cancer Centre. The transcript provides detailed insights into lung cancer care, molecular testing, and treatment access in Australia, reflecting the perspectives and experiences of the speakers without external data or claims.

Overview

This video features Dr. Doru Paul, an oncologist and hematologist at Weill Cornell Medical College, sharing his extensive clinical and research experience in cancer therapeutics. With over 33 years in oncology and treatment of more than 10,000 patients, Dr. Paul discusses recent advances such as immune checkpoint inhibitors, monoclonal antibodies, and innovative therapeutic strategies including the use of fluorodeoxyglucose (FDG) as a treatment modality.

Dr. Doru Paul's Background and Focus

Dr. Paul began his medical training in Romania and continued in France before moving to the United States. His clinical focus is on head and neck cancers, including throat, nasopharynx, and thyroid cancers, with additional experience in lung cancer. He combines clinical practice with translational research and theoretical biology to better understand cancer and develop less toxic, more effective treatments.

Immunotherapy and Monoclonal Antibodies

Dr. Paul highlights the significant progress in immunotherapy, particularly immune checkpoint inhibitors, which have transformed treatment options for advanced head and neck cancers. He explains that these therapies work by blocking the interaction between PD-L1 molecules on cancer cells and PD-1 receptors on T cells, thereby preventing the cancer from suppressing the immune response. This reactivation of T cells allows the immune system to attack and destroy cancer cells.

• Checkpoint inhibitors discussed include pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab, durvalumab, and cemiplimab.
• Monoclonal antibodies such as cetuximab (Erbitux) target specific proteins like the epidermal growth factor receptor (EGFR) on cancer cells.
• These agents can be used alone or in combination with chemotherapy and radiation, depending on the cancer stage and patient condition.

Dr. Paul notes that immunotherapy has improved survival rates beyond previous standards, with some patients living longer than a year with advanced disease, compared to about 10 months before these treatments.

Innovative Therapeutic Use of FDG

One of Dr. Paul's novel research areas involves using fluorodeoxyglucose (FDG), commonly used in PET scans for cancer detection, as a therapeutic agent. FDG is a radioactive glucose analog that cancer cells avidly uptake but cannot metabolize, effectively trapping it inside the cells.

• By administering higher doses of FDG, the emitted positrons deliver localized radiation that selectively kills cancer cells without harming surrounding normal tissues.
• This approach acts like a "smart bomb," targeting cancer cells within a limited radius and minimizing side effects.
• Early pilot studies with a small number of patients showed promising responses in various cancers, including lymphoma, head and neck, lung, and ovarian cancers.
• Dr. Paul suggests that low doses of FDG may also stimulate the immune system, potentially enhancing the effects of checkpoint inhibitors when combined.

This therapeutic use of FDG is still experimental and not yet widely available, but it represents a promising direction for less toxic cancer treatments.

Zooming Out: The Macroscopic View of Cancer and Metastasis

Dr. Paul emphasizes the importance of understanding cancer beyond the cellular and tissue levels by considering the organism-level interactions that drive metastasis, the cause of death in 90% of solid tumor patients.

• He describes a "triangulation" communication network between the primary tumor, metastatic sites, and bone marrow mediated by signaling molecules and exosomes.
• This communication prepares distant sites for metastasis by creating a supportive microenvironment, known as the premetastatic niche.
• Bone marrow-derived cells are recruited to assist in establishing these metastatic niches.
• Dr. Paul argues that targeting these macroscopic, organ-level pathological networks could open new avenues for cancer treatment beyond current cellular-level therapies.

This conceptual framework is part of Dr. Paul's recent research focus and represents a shift toward understanding cancer as a systemic disease involving complex inter-organ communication.

Current and Future Directions in Cancer Therapy

Dr. Paul discusses ongoing clinical trials combining multiple immunotherapy modalities, including oncolytic viruses, stereotactic body radiotherapy, and checkpoint inhibitors, aiming to stimulate the immune system more effectively and prevent cancer recurrence.

He also mentions emerging treatments like Lutetium-177 linked to antibodies targeting neuroendocrine tumors, which share conceptual similarities with the FDG therapeutic approach.

While immunotherapy remains at the forefront of cancer treatment, Dr. Paul anticipates that combination therapies and macroscopic-level targeting strategies may become more prominent in the next several years.

Clinical Practice and Research Integration

Dr. Paul exemplifies the clinician-researcher model, actively treating patients while conducting clinical trials and theoretical research. He holds a PhD in oncology focused on precision medicine and serves as director of clinical research, integrating scientific discoveries with patient care.

Source Information

This content is derived from a 30-minute video interview with Dr. Doru Paul hosted on the Brighteon platform, dated March 4, 2021. The discussion covers his background, clinical focus, and insights into cancer therapeutics, including immune checkpoint inhibitors, monoclonal antibodies, FDG-based therapy, and the systemic biology of metastasis. The transcript provides detailed explanations of mechanisms, clinical applications, and ongoing research efforts. The video is part of the Finding Genius Podcast series, which features expert interviews across scientific and medical fields.